Face To Face

As editor of the New England Journal of Medicine for more than a decade, Arnold S. Relman has played a significant role in setting publication standards for scientific journals. He champions the “Ingelfinger rule”promulgated by his predecessor, Franz Ingelfinger, which bars contributors from publicizing their articles before publication in the Journal. He also has strongly supported embargoes that permit reporters to receive advance copies of scientific journals on condition that th

Written byTabitha Powledge
| 13 min read

Register for free to listen to this article
Listen with Speechify
0:00
13:00
Share

Such policies have been challenged recently In its January 28 issue, the Journal published results of a clinical trial indicating that male physicians who took an aspirin every other day had fewer heart attacks than colleagues who took a placebo. The Reuters news agency ran a story on the study before the release date; Relman responded by suspending the wire service’s special airmail subscription for six months.

Q: Was there much controversy over your decision to publish the report by a committee of the University of California at San Diego on 137 articles by Robert A. Slutsky? RELMAN: No, I’m not aware of any. Q: Some of the articles that committee identified as either questionable or fraudulent have still not been retracted, apparently because the journals in question are worried about litigation. Is that fear appropriate? RELMAN: Fears about litigation are always appropriate in our litigious society. Whether they are ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies